BNP Paribas Financial Markets
SCNI

BNP Paribas Financial Markets’s Scinai Immunotherapeutics SCNI Stock Holding History

BNP Paribas Financial Markets’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-50
Closed -$8.3K – 4218
2022
Q1 		$8.3K Buy
+50
New +$7.26K ﹤0.01% 3826

Other funds holding SCNI

Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
TPWA
TRUE Private Wealth Advisors Salem, Oregon $1.16B AUM 36.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BNP Paribas Financial Markets's SCNI Position: Q2 2022 in Review

BNP Paribas Financial Markets sold out of Scinai Immunotherapeutics (SCNI) in Q2 2022, closing a stake of 50 shares — an estimated $8.3K sold.

BNP Paribas Financial Markets first reported a position in SCNI in Q1 2022 and held it in 1 quarter. The position peaked at $8.3K in Q1 2022. 14 funds tracked by Wall St. Rank hold SCNI as of Q2 2022.

  • BNP Paribas Financial Markets reported no remaining Scinai Immunotherapeutics position as of Q2 2022 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 50 Scinai Immunotherapeutics shares in Q2 2022, an estimated $8.3K.
  • BNP Paribas Financial Markets first reported a position in Scinai Immunotherapeutics in Q1 2022 and held it in 1 quarter.
  • BNP Paribas Financial Markets's Scinai Immunotherapeutics position peaked at $8.3K in Q1 2022.
  • 14 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q2 2022.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2022, filed 12 Aug 2022.